source
- Gubra aims to expand beyond obesity drugs, targets first portfolio partner this yearCopenhagen‑based biotech Gubra is currently known for its obesity drug candidates, but the company says its long‑term growth will depend on a broader pipeline beyond metabolism. The firm’s existin…
- GLP-1 drugs enter trials to test impact on alcohol and drug cravingsGLP-1 drugs, first approved for diabetes and later for obesity, have sparked interest for broader therapeutic uses. Researchers are now launching large clinical trials to evaluate whether these ag…